Kronox Lab Sciences Approves Audited FY26 Results and Recommends 5% Dividend
Kronox Lab Sciences reported audited standalone results for Q4FY26 and FY26. For Q4FY26, revenue from operations was ₹26.13 crore and profit after tax was ₹8.00 crore. For FY26, revenue from operations was ₹101.22 crore and profit after tax was ₹27.66 crore. The Board recommended a final dividend of 5% (₹0.50 per share).
The results show growth in key financial metrics and a dividend recommendation, which are positive for shareholders. The impact is considered medium as it reflects incremental growth rather than a significant turnaround or major new development.
The company reported an increase in revenue and profit for both the quarter and the full financial year. The recommendation of a dividend also contributes positively.
Kronox Lab Sciences Limited announced the outcome of its Board Meeting held on May 21, 2026. The Board approved the Audited Standalone Financial Results for the Quarter and Financial Year ended March 31, 2026. The company reported a total income of ₹28.27 crore for the quarter ended March 31, 2026, an increase from ₹26.41 crore in the same quarter last year. For the full financial year ended March 31, 2026, the total income stood at ₹106.41 crore, up from ₹102.72 crore in the previous year. Profit after tax for the quarter was ₹8.00 crore, compared to ₹6.59 crore in the corresponding quarter of the previous year. For the full year, profit after tax was ₹27.66 crore, an increase from ₹25.46 crore in FY25. Additionally, the Board recommended a final dividend of 5%, amounting to ₹0.50 per equity share (face value of ₹10), subject to shareholder approval.
The Board meeting commenced at 4:00 PM and concluded at 5:00 PM on May 21, 2026. The audited financial results were reviewed by statutory auditors, recommended by the Audit Committee, and approved by the Board. The company operates in a single reportable segment: manufacturing of High Purity Specialty Fine chemicals. The auditors issued an audit report with an unmodified opinion on the financial results.
What to do with a filing like this
Kronox Lab Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Kronox Lab Sciences Limited. Read the original for the full detail.